Fig. 6
From: RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
Chemical inhibition of RUNXs potentiates lenalidomide toxicity in primary multiple myeloma cells. a Primary MM cells were treated with DMSO, 0.1 μM lenalidomide, 1 μM AI-10-104, and combination. Every 2 days, viable cells were counted using Trypan blue exclusion assay. b The historical treatments of five MM patients are shown
